AEON Biopharma
AEON
Market cap $22.9M

0.5800 USD

-0.0170

2.85%

At close Nov 19, 4:00 PM EST

After hours

0.5400

-0.0400

6.90%

1 day

-2.85%

5 days

-22.77%

1 month

-42.57%

3 months

-42.00%

6 months

-65.88%

Year to date

-92.19%

1 year

-88.14%

5 years

-93.70%

10 years

-93.70%

About: AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Employees: 5

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,743 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

20% more funds holding

Funds holding: 25 [Q2] → 30 (+5) [Q3]

15% more capital invested

Capital invested by funds: $8.73M [Q2] → $10.1M (+$1.32M) [Q3]

0.13% more ownership

Funds ownership: 24.09% [Q2] → 24.22% (+0.13%) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

762%

upside

Avg. target

$5

762%

upside

High target

$5

762%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Douglas Tsao

52% 1-year accuracy

75 / 144 met price target

762%upside

$5

Buy

Reiterated

1 Oct 2024

See Analyst Rankings

Financial journalist opinion

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Zacks Investment Research

AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Zacks Investment Research

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround

AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline Current cash and cash equivalents expected to be sufficient to support corporate operations into Q4 2024; evaluating options to fund future advancement of late-stage clinical pipeline

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

AEON Biopharma Reports First Quarter 2024 Financial Results

– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints –

AEON Biopharma Reports First Quarter 2024 Financial Results

Zacks Investment Research

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AEON Biopharma Provides Update on Development Pipeline

Includes two late-stage clinical programs and two early-stage clinical programs Includes two late-stage clinical programs and two early-stage clinical programs

AEON Biopharma Provides Update on Development Pipeline

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint.

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

See News Rankings

Charts implemented using Lightweight Charts™